Subscribe
hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
10 December 2018Big Pharma

Appeal filed against EPO sofosbuvir patent decision

Six organisations have appealed against the European Patent Office’s (EPO) decision to uphold a patent for a key hepatitis C drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17 September 2018   The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Big Pharma
Medical tech leads 2020 innovation at the EPO
16 March 2021   Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17 September 2018   The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Big Pharma
Medical tech leads 2020 innovation at the EPO
16 March 2021   Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.

More on this story

Big Pharma
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17 September 2018   The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.
Big Pharma
Medical tech leads 2020 innovation at the EPO
16 March 2021   Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers